Lakewood-Amedex Biotherapeutics Inc. (LABT)

Lakewood-Amedex Biotherapeutics will go public soon, but the exact IPO date is still unknown.

Stock Price: Pending

IPO price not available yet

LABT Cash Flow Statement

Financials in millions usd. Fiscal year is January - December.

Millions usd. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-4.06	-4.86	-8.28
Depreciation & Amortization	0.12	0.05	0.04
Share-Based Compensation	-	0.27	0.61
Other Operating Activities	1.68	-1.19	0.81
Operating Cash Flow	-2.26	-5.72	-6.82
Capital Expenditures	0	-0	-
Change in Investments	-	3.93	-3.78
Investing Cash Flow	0.84	3.92	-3.78
Share Issuance / Repurchase	-	-0.05	-
Financing Cash Flow	1.5	-0.05	-
Net Cash Flow	0.08	-1.85	-10.6
Free Cash Flow	-2.26	-5.73	-6.82

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).